- Home
- CGNT vs AVXL Comparison
CGNT vs AVXL Comparison
Compare CGNT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- AVXL
- Stock Information
- Founded
- CGNT 2020
- AVXL 2001
- Country
- CGNT Israel
- AVXL United States
- Employees
- CGNT N/A
- AVXL N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGNT Technology
- AVXL Health Care
- Exchange
- CGNT Nasdaq
- AVXL Nasdaq
- Market Cap
- CGNT 743.4M
- AVXL 779.5M
- IPO Year
- CGNT N/A
- AVXL N/A
- Fundamental
- Price
- CGNT $9.14
- AVXL $8.35
- Analyst Decision
- CGNT Hold
- AVXL Strong Buy
- Analyst Count
- CGNT 3
- AVXL 2
- Target Price
- CGNT $8.25
- AVXL $44.00
- AVG Volume (30 Days)
- CGNT 288.0K
- AVXL 995.5K
- Earning Date
- CGNT 04-08-2025
- AVXL 02-12-2025
- Dividend Yield
- CGNT N/A
- AVXL N/A
- EPS Growth
- CGNT N/A
- AVXL N/A
- EPS
- CGNT N/A
- AVXL N/A
- Revenue
- CGNT $339,818,000.00
- AVXL N/A
- Revenue This Year
- CGNT $13.67
- AVXL N/A
- Revenue Next Year
- CGNT $6.92
- AVXL N/A
- P/E Ratio
- CGNT N/A
- AVXL N/A
- Revenue Growth
- CGNT 12.16
- AVXL N/A
- 52 Week Low
- CGNT $6.21
- AVXL $3.25
- 52 Week High
- CGNT $11.12
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- CGNT 38.71
- AVXL 40.39
- Support Level
- CGNT $10.52
- AVXL $8.50
- Resistance Level
- CGNT $10.91
- AVXL $9.20
- Average True Range (ATR)
- CGNT 0.43
- AVXL 0.49
- MACD
- CGNT -0.17
- AVXL -0.01
- Stochastic Oscillator
- CGNT 13.54
- AVXL 32.23
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.